BioSpace News Archive

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, announced that effective today it has appointed Andrei Floroiu as Chief Executive Officer.

Repligen Corporation (NASDAQ:RGEN) today announced the appointment of healthcare industry executive Carrie Eglinton Manner to its Board of Directors.

Four Scientific Poster Presentations Support the Potential of INP104 to Fulfill Key Unmet Needs and If Approved, Become a Transformative New Therapeutic Option for Acute Migraine Additional Data from STOP 301, the Company’s Pivotal Phase 3 Study of INP104 for Acute Migraine, Found Majority of Patients Reported INP104 Easy to Use and Preferred Over Current Acute Therapy Impel NeuroPharma Plans to Submit a New Drug Application (NDA) in the Second Half of 2020

Parkway Clinical Laboratories Inc. (PCL), today announced it has launched COVID-19 Immune Response Serum Immunoglobin IGG Antibody test available directly to consumers.

More Than 97% Of Notes Sought Were Tendered And Accepted Thereby Extending More Than $2.7 Billion Of Endo International plc’s Near-Term Debt Maturities

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that Catalent Biologics will provide vial filling and packaging capacity to AstraZeneca PLC

Seelos Therapeutics, Inc. (SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will host a key opinion leader (KOL) call to provide updates regarding data from the Phase I study of SLS-002 on Tuesday, June 23, 2020 at 1:00 p.m. Eastern Time. Seelos will also provide an overview of the design for Seelos’ next study of SLS-002 for Acute

Extendicare Inc. announced that it has declared a cash dividend of C$0.04 per common share of the Company for the month of June 2020, which is payable on July 15, 2020 to shareholders of record at the close of business on June 30, 2020.

Contraceptive Program Supported by up to $20.5 Million in Grant Funding from the Bill & Melinda Gates Foundation

Motus GI Holdings, Inc. announced that physicians and hospitals using the Pure-Vu® System will now have on-demand access to a full spectrum of Motus support and educational resources via the new Motus GI mobile app, which was launched.